Servier acquires Pixuvri from CTI BioPharma by Anna Smith | Oct 3, 2019 | News | 0 The treatment was approved for use in the European Union in June this year. Read More
CTI, Servier’s Pixuvri fails in post-marketing trial by Selina McKee | Jul 10, 2018 | News | 0 A late-stage trial of Servier and CTI BioPharma’s Pixuvri in combination with Roche’s MabThera has failed to hit targets in B-cell non-Hodgkin lymphoma, putting its conditional approval in Europe in jeopardy. Read More